Berkshire Hathaway (BRK.A) (BRK.B) stock remained subdued in the back half of 2025 as markets digested the surprise announcement of Warren Buffett’s departure as chief executive on Dec. 31. And while transitional uncertainty is undeniable, there are ample reasons to believe BRK.B shares, under the leadership of incoming CEO Greg Abel, will recover some of their lost ground in 2026. More News from Barchart Berkshire Hathaway stock is on track to close this year with a 12% gain, significantly below 18% f ...

Group 1 - The marketplace channel Haggerston BioHealth offers exclusive stock tips focused on Pharma, Biotech, and Healthcare, providing access to investment bank-grade financial models and research [1] - The group caters to both novice and experienced biotech investors, offering insights on catalysts, buy and sell ratings, product sales forecasts, and integrated financial statements [2] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group and has compiled detailed reports on over 1,000 companies [2]